Last updated: April 17, 2018
Sponsor: University of Aarhus
Overall Status: Active - Recruiting
Phase
4
Condition
Sarcopenia
Polymyositis (Inflammatory Muscle Disease)
Neuropathy
Treatment
N/AClinical Study ID
NCT03510546
Mestinon2018
Ages 18-90 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- MG verified by a) anti-body, or b) single-fiber EMG and/or decrement on ENG.
Exclusion
Exclusion Criteria:
Anti-MuSK
Known cardio-pulmonary disease
Known neuropathy
Known myopathy
Known malignant disease
Pregnancy or breastfeeding
Mechanic ileus, urinary tract obstruction, peritonitis De-novo MG Eligibility Criteria
MG diagnosis < 2 months, no prior antimyasthenic medications Chronic MG Eligibility Criteria
MG diagnosis > 1 year, and stable pyridostigmine dosis
Study Design
Total Participants: 44
Study Start date:
April 09, 2018
Estimated Completion Date:
August 31, 2021
Study Description
Connect with a study center
Department of Neurology Aarhus University Hospital
Aarhus, Midtjylland 8000
DenmarkActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.